

ADVENTRX PHARMACEUTICALS INC  
 Form 4  
 April 15, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 LEVINE EVAN

2. Issuer Name and Ticker or Trading Symbol  
 ADVENTRX  
 PHARMACEUTICALS INC [ANX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
 6725 MESA RIDGE RD., STE. 100  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 10/04/2004

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 CEO & President

SAN DIEGO, CA 92121

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	10/04/2004		P		2,300	A	\$ 1.19	4,382,300	D
Common Stock	10/04/2004		P		700	A	\$ 1.19	4,383,000	D
Common Stock	10/26/2004		P		100	A	\$ 0.93	4,383,100	D
Common Stock	10/26/2004		P		100	A	\$ 0.93	4,383,200	D
Common Stock	10/26/2004		P		500	A	\$ 0.93	4,383,700	D

## Edgar Filing: ADVENTRX PHARMACEUTICALS INC - Form 4

Common Stock	10/26/2004	P	1,500	A	\$ 0.93	4,385,200	D
Common Stock	10/26/2004	P	400	A	\$ 0.93	4,385,600	D
Common Stock	10/26/2004	P	100	A	\$ 0.93	4,385,700	D
Common Stock	10/26/2004	P	400	A	\$ 0.93	4,386,100	D
Common Stock	10/26/2004	P	100	A	\$ 0.93	4,386,200	D
Common Stock	11/30/2004	P	1,800	A	\$ 0.86	4,388,000	D
Common Stock	03/22/2005	S	3,000	D	\$ 1.5	4,385,000	D
Common Stock	10/27/2005	S	3,800	D	\$ 3.16	4,381,200	D
Common Stock	01/03/2006	S	1,200	D	\$ 3.22	4,380,000	D
Common Stock	01/06/2006	P	900	A	\$ 3.86	4,380,900	D
Common Stock	01/06/2006	P	100	A	\$ 3.86	4,381,000	D
Common Stock	01/06/2006	P	1,000	A	\$ 3.87	4,382,000	D
Common Stock	02/23/2006	S	2,000	D	\$ 4.29	4,380,000	D
Common Stock	05/01/2006	P	1,000	A	\$ 5.15	4,381,000	D
Common Stock	05/05/2006	P	1,000	A	\$ 4.47	4,382,000	D
Common Stock	05/18/2006	P	1,000	A	\$ 4.36	4,383,000	D
Common Stock	06/19/2006	P	1,000	A	\$ 3.15	4,384,000	D
Common Stock	07/24/2006	S	1,000	D	\$ 2.82	4,383,000	D
Common Stock	11/13/2006	P	1,000	A	\$ 2.63	4,384,000	D
Common Stock	10/22/2007	S	900	D	\$ 0.6012	4,383,100	D
	10/22/2007	S	100	D	\$ 0.601	4,383,000	D

Common Stock								
Common Stock	11/19/2007		S	3,000	D	\$ 0.59	4,380,000	D
Common Stock	02/04/2008		P	5,000	A	\$ 0.42	4,385,000	D
Common Stock	02/05/2008		P	3,000	A	\$ 0.43	4,388,000	D
Common Stock	02/05/2008		P	2,000	A	\$ 0.42	4,390,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Beneficially (Instr. 5)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LEVINE EVAN 6725 MESA RIDGE RD., STE. 100 SAN DIEGO, CA 92121	X		CEO & President	

## Signatures

/s/ Evan Levine                      04/15/2008  
 \*\*Signature of                      Date  
 Reporting Person

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

### Remarks:

All of the transactions reported herein were executed by the Reporting Person's father through a brokerage account in the name of the Reporting Person and his father as joint tenants with right of survivorship. The Reporting Person did not contribute any funds to this brokerage account or direct any of transactions reported herein. The Reporting Person was not alerted to these transactions until February 2008.

Certain of the Reporting Person's sales of the Issuer's common stock reported herein were matchable under Section 16(b) of the Exchange Act of 1934, as amended, to certain of the Reporting Person's purchases of the Issuer's common stock reported herein. The Reporting Person has paid to the Issuer a total of \$4,397.18, representing the full amount of the recoverable profit from the "swing" transactions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.